James W Neely, DO | |
1608 E Evergreen St, Suite A, Cameron, MO 64429-2400 | |
(816) 632-3945 | |
(816) 632-3940 |
Full Name | James W Neely |
---|---|
Gender | Male |
Speciality | Family Medicine |
Location | 1608 E Evergreen St, Cameron, Missouri |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1962486951 | NPI | - | NPPES |
7850046 | Other | MO | MEDICARE PART B |
242446870 | Medicaid | MO | |
10050637 | Other | MO | MEDICARE RAILROAD |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | R4G44 (Missouri) | Primary |
Entity Name | Cameron Regional Medical Center Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1811905375 PECOS PAC ID: 5092622001 Enrollment ID: O20040113000619 |
News Archive
Oncolytics Biotech Inc. announced today that enrollment has been completed in a U.K. translational clinical trial investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases.
OsteoRemedies®, LLC, Memphis, TN, offers the first FDA-approved modular system for two-stage revision of infected hip and knee arthroplasty.
An analysis of brain tissue samples from chronic alcoholics reveals changes that occur at the molecular level in alcohol abuse - and suggests a potential treatment target, according to researchers from Wake Forest University School of Medicine.
Oncotarget published "Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations" which reported that unlike lung adenocarcinoma patients, there is no FDA-approved targeted-therapy likely to benefit lung squamous cell carcinoma patients.
› Verified 3 days ago
Entity Name | Salem Memorial Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1114177557 PECOS PAC ID: 7012801129 Enrollment ID: O20040210000857 |
News Archive
Oncolytics Biotech Inc. announced today that enrollment has been completed in a U.K. translational clinical trial investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases.
OsteoRemedies®, LLC, Memphis, TN, offers the first FDA-approved modular system for two-stage revision of infected hip and knee arthroplasty.
An analysis of brain tissue samples from chronic alcoholics reveals changes that occur at the molecular level in alcohol abuse - and suggests a potential treatment target, according to researchers from Wake Forest University School of Medicine.
Oncotarget published "Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations" which reported that unlike lung adenocarcinoma patients, there is no FDA-approved targeted-therapy likely to benefit lung squamous cell carcinoma patients.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
James W Neely, DO 1600 E Evergreen St, Po Box 557, Cameron, MO 64429-2400 Ph: (816) 632-2101 | James W Neely, DO 1608 E Evergreen St, Suite A, Cameron, MO 64429-2400 Ph: (816) 632-3945 |
News Archive
Oncolytics Biotech Inc. announced today that enrollment has been completed in a U.K. translational clinical trial investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases.
OsteoRemedies®, LLC, Memphis, TN, offers the first FDA-approved modular system for two-stage revision of infected hip and knee arthroplasty.
An analysis of brain tissue samples from chronic alcoholics reveals changes that occur at the molecular level in alcohol abuse - and suggests a potential treatment target, according to researchers from Wake Forest University School of Medicine.
Oncotarget published "Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations" which reported that unlike lung adenocarcinoma patients, there is no FDA-approved targeted-therapy likely to benefit lung squamous cell carcinoma patients.
› Verified 3 days ago
Lindsay J Rice, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 215 S Walnut St, Cameron, MO 64429 Phone: 816-632-1799 Fax: 816-632-5688 | |
Dr. James Kay Stoneking, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1111 Euclid Dr., Veterans Cboc, Cameron, MO 64429 Phone: 816-861-4700 Fax: 816-632-1962 | |
Dr. Laura Leigh Harbison, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 221 E 7th, Cameron, MO 64429 Phone: 816-632-2111 Fax: 816-632-7929 | |
Dr. Betsy Anne Fox Mcclure, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2401 Se Hwy 36, Cameron, MO 64429 Phone: 816-632-2415 | |
John S Barton Iii, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 E Evergreen St, Suite C, Cameron, MO 64429 Phone: 816-632-2139 Fax: 816-632-2315 |